The Oncology Institute (TOI) Earnings Analysis
The Oncology Institute (TOI) next reports earnings on 2026-08-12, consensus EPS -0.07 USD. Last quarter (2026-05-07) it beat with EPS -0.02 USD vs -0.07 USD est (+71.4%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -15.11.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does TOI next report earnings?
| Next earnings date | 2026-08-12 |
|---|---|
| Consensus EPS estimate | -0.07 USD |
| Revenue estimate | 0.16B |
TOI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.02 USD | -0.07 USD | +71.4% | Beat |
| 2026-03-12 | -0.06 USD | -0.08 USD | +25% | Beat |
| 2025-11-13 | -0.14 USD | -0.12 USD | -16.7% | Miss |
| 2025-08-13 | -0.14 USD | -0.14 USD | 0% | Beat |
| 2025-05-14 | -0.17 USD | n/a | n/a | n/a |
| 2025-03-24 | -0.14 USD | -0.08 USD | -75% | Miss |
Beat rate: 3/5 (60%) over reported quarters with consensus data.
TOI valuation and analyst view
| Trailing P/E | -15.11 |
|---|---|
| Trailing EPS | -0.04274 USD |
| Price / book | -330.69 |
| Dividend yield | 0.00% |
| Market cap | 0.53B |
| Analyst consensus | Buy (5 buy / 0 hold / 0 sell) |
| Avg price target | 8.5 USD |
Related research pages
Frequently asked questions
When is The Oncology Institute (TOI)'s next earnings date?
The Oncology Institute is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.07 USD and revenue estimate of 0.16B.
Did TOI beat earnings last quarter?
In its 2026-05-07 report, TOI posted EPS of -0.02 USD versus a -0.07 USD estimate — a beat of 71.4%.
What is TOI's earnings track record?
Over the last 5 reported quarters with consensus data, TOI beat estimates 3 times (60%).
What is TOI's current P/E ratio and EPS?
TOI trades at a trailing P/E of -15.11 on trailing EPS of -0.042742939357667716 USD.
What do analysts rate TOI?
Analyst consensus is "Buy" across 5 ratings (0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 8.5 USD.